The Shanghai Stock Exchange disclosed the announcement of the 2019th deliberation meeting of the Listing Committee of the Science and Technology Innovation Board in 29, and Shenzhen Pumen Technology Co., Ltd. was first listed on October 10.

 

Shenzhen Pumen Technology Co., Ltd. is a national high-tech enterprise, established on January 2008, 01. The main business of the enterprise is the research and development, production and sales of treatment and rehabilitation products, in vitro diagnostic equipment and supporting reagents. The reason why a company is bound to go public is inseparable from its excellent innate genes.

 

 

Financial data show that the operating income of Pumen Technology during the reporting period was 1 million yuan, 74 million yuan, 2 million yuan and 5 million yuan, respectively. The company has maintained a high proportion of capital investment in product research and development. According to the prospectus, from 3 to 2, the proportion of the company's R&D expenses to operating income was 2.05%, 2016.2018% and 22.6%, respectively, all higher than the red line of "R&D accounted for not less than 19%", even in the first half of this year, the company's R&D ratio reached 92.20%. Pumen Technology is committed to the research and development and industrialization of in vitro diagnostic equipment, rehabilitation treatment equipment, and household medical equipment. Adhering to technological innovation as the foundation, clinical diagnosis and treatment as the guide, and enhancing the core competitiveness of the industry, 61 municipal innovative R&D institutions and a number of advanced professional laboratories have been built, including Guangdong Academician Workstation, Guangdong Engineering Technology Research Center, Shenzhen Engineering Laboratory, Optical Laboratory, Instrument Development Laboratory, etc.

 

 

The company adheres to independent research and development, and has 100% own intellectual property rights for all products. Pumen Technology adheres to scientific management, fully implements ERP and other information systems, creates a perfect information management platform, and strictly follows the ISO13485 standard of medical device quality system and 5 s production site management specifications to ensure that customers are provided with high-quality products. Accelerate the global demand in the field of rehabilitation treatment and in vitro diagnostics, deeply implement the international strategy, and strive to build a global sales and service system. Series products have gone abroad, foreign installed customers are distributed in dozens of countries including Russia, Britain, Germany, France, Italy and so on. At present, Pumen Technology has established a complete sales network and service network in China, the company is based in Shenzhen, in the main central cities of the country (Beijing, Shanghai, Guangzhou, Chengdu, Nanjing, etc.) set up offices and customer service agencies, and has hundreds of dealers with good cooperation. A series of diagnosis and treatment equipment has been installed and used in more than 301,<> medical institutions across the country, including Beijing <> Hospital, Peking Union Medical College Hospital and other tertiary high-end hospitals, creating good social and economic benefits for medical institutions, and has been highly praised by clinicians and patients.

Pumen Technology is the first enterprise in China's medical device industry to win the first prize of National Science and Technology Progress Award.

 

 

Pumen Technology has won many awards, including: "First Prize of National Science and Technology Progress Award", "National High-tech Enterprise", "Shenzhen High-tech Enterprise", "AAA Certificate of Enterprise Credit Rating", "Leading Brand of China's Industry" and so on. The company has received capital injection from many investment companies such as SoftBank China Capital, Shenzhen Venture Capital, Qianhai Fund of Funds, Yifeng Investment, Huatai Zijin, Songhe Capital, and Tongchuang Weiye.